Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Malaysia's IHH Healthcare may be entitled to damages of up to $1.25 billion from Japan's Daiichi Sankyo for blocking its bid ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...

IHH Healthcare's Singaporean subsidiary, Northern TK Venture, has raised its damage claim against Japan's Daiichi Sankyo in a Tokyo court to JPY 199.8 billion amid a legal battle over a stalled open ...

IHH Healthcare said on Thursday its unit has sought up to 109.3 billion rupees ($1.25 billion) in compensation from Japan's ...